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tobacco dependence and smoking-
associated diseases (Bierut et al,
2008; Thorgeirsson et al, 2008).
In particular, a polymorphism in
CHRNA5 (rs16969968) that results in
an aspartic acid to asparagine sub-
stitution at amino-acid reside 398
(D398N) more than doubles the risk
of tobacco dependence in those carry-
ing two copies of the risk allele. Little
was known about how nAChRs-con-
taining a5, a3, and/or b4 subunits may
contribute to tobacco dependence.
However, recent findings suggest that
nAChRs containing these subunits
play a key role in regulating nicotine
reinforcement.
The a3, a5, and b4 nAChR subunits
are densely expressed in the medial
habenula (MHb) and its major site
of projection, the interpeduncular
nucleus (IPN) (Salas et al, 2009). Our
laboratory has recently shown that
mice with null mutation in the a5
nAChR subunit gene intravenously
self-administer significantly greater
quantities of nicotine than their wild-
type counterparts, particularly when
higher unit doses of the drug are
available for consumption (Fowler
et al, 2011). This enhanced intake in
the mutant mice was ameliorated by
virus-mediated re-expression of a5
nAChR subunits in the MHb–IPN
tract. In addition, we found that IPN
neurons were insensitive to nicotine in
the mutant mice, reflected in greatly
diminished induction of Fos immu-
noreactivity in response to nicotine
injections. Moreover, lidocaine-in-
duced inactivation of the MHb or
IPN increased nicotine self-adminis-
tration in rats, particularly at higher
units doses of the drug. Finally, virus-
mediated knockdown of a5 nAChR
subunits in the MHb–IPN tract did
not alter the reward-enhancing prop-
erties of lower nicotine doses, but
greatly attenuated the reward-inhibit-
ing (ie, aversive) effects of higher
nicotine doses in rats (Fowler et al,
2011). In keeping with these findings,
overexpression of b4 nAChR subunits
in the MHb–IPN tract enhanced aver-
sion to nicotine and reduced con-
sumption of the drug in mice (Frahm
et al, 2011). Moreover, virus-mediated
expression in the MHb of a major risk
allele of the a5 subunit gene (D398N
allele), which decreases the function of
a5-containing nAChRs incorporating
this risk allele and increases vulner-
ability to tobacco dependence in
humans, reduced aversion to nicotine
and enhanced nicotine intake in
the b4 subunit-overexpressing mice
(Frahm et al, 2011). Hence, nAChRs-
containing a5 and/or b4 subunits
regulate the activation of the MHb–
IPN tract in response to nicotine,
which signals aversion to the drug.
Deficient nAChR signaling in the
MHb–IPN tract, which likely occurs
in humans carrying risk alleles in the
CHRNA3-CHRNA5-CHRNB4 gene clus-
ter, reduces nicotine aversion and results
in greater consumption of the drug. As
such, these finding reveal fundamental
new insights into the mechanisms of
nicotine reinforcement and the neuro-
circuitry of tobacco dependence.
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Circuits, Cells, and
Synapses: Toward a
New Target for Deep
Brain Stimulation in
Depression
Understanding the pathophysiology of
depression requires knowledge of the
anatomical pathways that malfunction
in this disorder. The anatomy of
depression involves limbic and hypo-
thalamic activation mediating stress
and anxiety. These interact with
cortical areas, primarily the medial
prefrontal cortex (mPFC), which ap-
pears to mediate the cognitive aspects
of depression. The mPFC in turn
innervates the thalamus and lateral
habenula (l. habenula). The anatomy
of melancholia has recently been ad-
vanced through an understanding of
the role of the l. habenula and incor-
poration of this structure between the
cortical and limbic inputs and the
monoaminergic nuclei. The l. habenula
controls the midbrain monoaminergic
nuclei, whose output pathways interact
with each other, as well as providing
strong modulatory control of limbic
and cortical areas. Recently under-
standing of how the dopamine system
is regulated by the l. habenula in
normal (Matsumoto and Hikosaka,
2009) and affectively disturbed states
(Li et al, 2011) has been investigated.
Over activity in the l. habenula is seen
in both the learned helplessness model
(Li et al, 2011) and in patients who
express depressive symptoms following
tryptophan depletion (Roiser et al,
2009). This over activity causes de-
creased dopaminergic stimuation, sup-
pressing reward signals (Matsumoto
and Hikosaka, 2009). It also depresses
5HT signals (Wang and Aghajanian,
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1997), which feed back further in-
creasing l. habenular activity. The
l. habenula receives strong inputs
from both the limbic system, through
the basal nucleus of the stria termina-
lis, which carries information from the
amygdala related to anxiety and from
the mPFC, which may be related to
the cognitive aspects of depression
(Li et al, 2011) and sends its output to
the midbrain aminergic nuclei.
Because it appears the l. habenula
functions as a control center that
regulates the reward center, modulat-
ing cortical, and limbic areas, it might
be an ideal target for deep brain
stimulation in cases of intractable,
treatment-resistant depression. This
has been utilized for a single patient
and resulted in a total remission
(Sartorius et al, 2010) that rapidly
reversed when the stimulator was
disconnected and returned after the
stimulation was reinstated. The time
course for the remission after initiat-
ing stimulation is slow, weeks for full
remission, suggesting that structural
changes underlie this effect. High
frequency and high voltage stimula-
tion inhibit l. habenula slice activity
(Li et al, 2011) supporting the concept
that inhibition occurs through DBS
and this may well be the mechanism
through which DBS acts (Figure 1).
Glutaminergic over activity in the
mPFC drives the over activation of
the l. habenula (Li et al, 2011) in the
chronically helpless line of animals,
allowing the development of a depres-
sive state mediated, in part, by altered
monoaminergic function. Excess cor-
tical glutamate in the mPFC, resulting
from stress, leads to decreases in
cortical synapses, a well-documented
effect that can be reversed by keta-
mine. Chronically helpless animals
show a 40% loss of synapses, suggest-
ing enhanced stress sensitivity. The
excess glutamate appears to be sus-
tained through decreased astrocytic
glutamate transporter in these learned
helpless animals (Zink et al, 2010),
suggesting that astrocytic dysfunction
may be a fundamental step in the
pathophysiology of depression.
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Update on
Corticotropin-Releasing
Factor Pharmacotherapy
for Psychiatric
Disorders: A Revisionist
View
The identification of corticotropin-
releasing factor (CRF) in 1981 was
followed by the discovery of three CRF
paralogs (urocortins 1, 2, and 3) and
two CRF/urocortin receptors (CRF1,
CRF2; Bale and Vale, 2004). Because
preclinical studies showed that CRF1
receptors mediate endocrine, behavior-
al, and autonomic responses to stress,
the pharmaceutical industry developed
blood–brain barrier-penetrating CRF1
receptor antagonists. We and others
previously surveyed the pharmacology
of non-peptide CRF1 receptor antago-
nists and the therapeutic rationale of
CRF1 antagonists for major depression,
anxiety disorders, and addiction (see
Koob and Zorrilla, 2010; Zorrilla and
Koob, 2010, for references). Yet, CRF1
antagonists have still not yielded posi-
tive Phase III clinical trials, prompting
the current revisionist view of the
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Figure 1. Principal inputs and outputs of the l. habenula crossroad in the circuit mediating
depression.
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